|
1
|
Chan JC, Malik V, Jia W, Kadowaki T,
Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: Epidemiology, risk
factors, and pathophysiology. JAMA. 301:2129–2140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guariguata L, Whiting DR, Hambleton I,
Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes
prevalence for 2013 and projections for 2035. Diabetes Res Clin
Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamblin N, Fertin M, De Groote P and
Bauters C: Cardiac remodeling and heart failure after a first
anterior myocardial infarction in patients with diabetes mellitus.
J Cardiovasc Med (Hagerstown). 13:353–359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tochiya M, Makino H, Tamanaha T, Matsuo M,
Hishida A, Koezuka R, Ohata Y, Tomita T, Son C, Miyamoto Y, et al:
Effect of tofogliflozin on cardiac and vascular endothelial
function in patients with type 2 diabetes and heart diseases: A
pilot study. J Diabetes Investig. 11:400–404. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sardu C, Barbieri M, Santamaria M,
Giordano V, Sacra C, Paolisso P, Spirito A, Marfella R, Paolisso G
and Rizzo MR: Multipolar pacing by cardiac resynchronization
therapy with a defibrillators treatment in type 2 diabetes mellitus
failing heart patients: Impact on responders rate, and clinical
outcomes. Cardiovasc Diabetol. 16:752017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kannel WB and McGee DL: Diabetes and
cardiovascular disease: The Framingham study. JAMA. 241:2035–2038.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lind M, Bounias I, Olsson M,
Gudbjörnsdottir S, Svensson AM and Rosengren A: Glycaemic control
and incidence of heart failure in 20,985 patients with type 1
diabetes: An observational study. Lancet. 378:140–146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bayeva M, Sawicki KT and Ardehali H:
Taking diabetes to heart-deregulation of myocardial lipid
metabolism in diabetic cardiomyopathy. J Am Heart Assoc.
2:e4332013. View Article : Google Scholar
|
|
9
|
Xu Y, Wang L, He J, Bi Y, Li M, Wang T,
Wang L, Jiang Y, Dai M, Lu J, et al: Prevalence and control of
diabetes in Chinese adults. JAMA. 310:948–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim HW, Ch YS, Lee HR, Park SY and Kim YH:
Diabetic alterations in cardiac sarcoplasmic reticulum
Ca2+-ATPase and phospholamban protein expression. Life
Sci. 70:367–379. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai L, Li W, Wang G, Guo L, Jiang Y and
Kang YJ: Hyperglycemia-induced apoptosis in mouse myocardium:
Mitochondrial cytochrome C-mediated caspase-3 activation pathway.
Diabetes. 51:1938–1948. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Way KJ, Isshiki K, Suzuma K, Yokota T,
Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ,
Wakasaki H and King GL: Expression of connective tissue growth
factor is increased in injured myocardium associated with protein
kinase C beta2 activation and diabetes. Diabetes. 51:2709–2718.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Candido R, Forbes JM, Thomas MC, Thallas
V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME
and Burrell LM: A breaker of advanced glycation end products
attenuates diabetes-induced myocardial structural changes. Circ
Res. 92:785–792. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Catterall WA: Structure and regulation of
voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol.
16:521–555. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dolphin AC: Voltage-gated calcium
channels: Their discovery, function and importance as drug targets.
Brain Neurosci Adv. 2:23982128187948052018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Klingbeil AU, Schneider M, Martus P,
Messerli FH and Schmieder RE: A meta-analysis of the effects of
treatment on left ventricular mass in essential hypertension. Am J
Med. 115:41–46. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fagard RH, Celis H, Thijs L and Wouters S:
Regression of left ventricular mass by antihypertensive treatment:
A meta-analysis of randomized comparative studies. Hypertension.
54:1084–1091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Puscas L, Gilau L, Coltau M, Pasca R,
Domuta G, Baican M and Hecht A: Calcium channel blockers reduce
blood pressure in part by inhibiting vascular smooth muscle
carbonic anhydrase I. Cardiovasc Drug Ther. 14:523–528. 2000.
View Article : Google Scholar
|
|
19
|
Bangalore S, Fakheri R, Toklu B and
Messerli FH: Diabetes mellitus as a compelling indication for use
of renin angiotensin system blockers: Systematic review and
meta-analysis of randomized trials. BMJ. 352:i4382016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Packer M, O'Connor CM, Ghali JK, Pressler
ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer
JH, et al: Effect of amlodipine on morbidity and mortality in
severe chronic heart failure. Prospective randomized amlodipine
survival evaluation study group. N Engl J Med. 335:1107–1114. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu J, Hao J, Du H, Xiao B, Li Y, Yang X
and Cui W: Amlodipine and atorvastatin improved hypertensive
cardiac remodeling through regulation of MMPs/TIMPs in SHR RATS.
Cell Physiol Biochem. 39:47–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagasawa K, Takahashi K, Matsuura N,
Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T
and Nagata K: Comparative effects of valsartan in combination with
cilnidipine or amlodipine on cardiac remodeling and diastolic
dysfunction in Dahl salt-sensitive rats. Hypertens Res. 38:39–47.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Whittaker P, Zhang HP and Kloner RA:
Biphasic survival response to amlodipine after myocardial
infarction in rats: Association with cardiac vascular remodeling.
Cardiovasc Pathol. 2:85–93. 2000. View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta CT) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verkhratsky A and Fernyhough P:
Mitochondrial malfunction and Ca2+ dyshomeostasis drive
neuronal pathology in diabetes. Cell Calcium. 1:112–122. 2008.
View Article : Google Scholar
|
|
26
|
Jouven X, Lemaître RN, Rea TD, Sotoodehnia
N, Empana JP and Siscovick DS: Diabetes, glucose level, and risk of
sudden cardiac death. Eur Heart J. 26:2142–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeung EH, Pankow JS, Astor BC, Powe NR,
Saudek CD and Kao WH: Increased risk of type 2 diabetes from a
family history of coronary heart disease and type 2 diabetes.
Diabetes Care. 30:154–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rubler S, Dlugash J, Yuceoglu YZ, Kumral
T, Branwood AW and Grishman A: New type of cardiomyopathy
associated with diabetic glomerulosclerosis. Am J Cardiol.
30:595–602. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bergner DW and Goldberger JJ: Diabetes
mellitus and sudden cardiac death: What are the data? Cardiol J.
17:117–129. 2010.PubMed/NCBI
|
|
30
|
Aharinejad S, Andrukhova O, Lucas T,
Zuckermann A, Wieselthaler G, Wolner E and Grimm M: Programmed cell
death in idiopathic dilated cardiomyopathy is mediated by
suppression of the apoptosis inhibitor apollon. Ann Thorac Surg.
86:109–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang ZY, Schull-Meade R, Leano R, Mottram
PM, Prins JB and Marwick TH: Screening for heart disease in
diabetic subjects. Am Heart J. 149:349–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boyer JK, Thanigaraj S, Schechtman KB and
Pérez JE: Prevalence of ventricular diastolic dysfunction in
asymptomatic, normotensive patients with diabetes mellitus. Am J
Cardiol. 93:870–875. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boudina S and Abel ED: Diabetic
cardiomyopathy, causes and effects. Rev Endocr Metab Disord.
11:31–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanai M, Otsuka Y, Otsuka K, Sato M,
Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S,
et al: A phase I study investigating the safety and
pharmacokinetics of highly bioavailable curcumin (Theracurmin) in
cancer patients. Cancer Chemother Pharmacol. 71:1521–1530. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sasaki H, Sunagawa Y, Takahashi K,
Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H,
Fujita M, et al: Innovative preparation of curcumin for improved
oral bioavailability. Biol Pharm Bull. 34:660–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Heerebeek L, Hamdani N, Handoko ML,
Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ,
Schalkwijk CG, Bronzwaer JG, Diamant M, et al: Diastolic stiffness
of the failing diabetic heart: Importance of fibrosis, advanced
glycation end products, and myocyte resting tension. Circulation.
117:43–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gonzalez-Quesada C, Cavalera M, Biernacka
A, Kong P, Lee DW, Saxena A, Frunza O, Dobaczewski M, Shinde A and
Frangogiannis NG: Thrombospondin-1 induction in the diabetic
myocardium stabilizes the cardiac matrix in addition to promoting
vascular rarefaction through angiopoietin-2 upregulation. Circ Res.
113:1331–1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li MD, Cheng WP, Shi MX, Ge TD, Zheng XL,
Wu DY, Hu XY, Luo JC, Li FL and Li H: Role of tRNA selenocysteine 1
associated protein 1 in the proliferation and apoptosis of
cardiomyocyte-like H9c2 cells. Mol Med Rep. 15:988–994. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saito M, Sakiyama K, Shiota T and Ito M:
Isoproterenol produces a rapid increase in sialidase activity in
rat heart tissue and cardiomyocyte-derived H9c2 cells in culture.
FEBS Lett. 542:105–108. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watkins SJ, Borthwick GM and Arthur HM:
The H9C2 cell line and primary neonatal cardiomyocyte cells show
similar hypertrophic responses in vitro. In Vitro
Cell Dev Biol Anim. 47:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diedrichs H, Chi M, Boelck B, Mehlhorn U
and Schwinger RH: Increased regulatory activity of the
calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail.
6:3–09. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haq S, Choukroun G, Lim H, Tymitz KM, del
Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T and
Molkentin JD: Differential activation of signal transduction
pathways in human hearts with hypertrophy versus advanced heart
failure. Circulation. 103:670–677. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu SJ, Yang YJ, Yu LJ and Huang L:
CaN-NFAT3 signal pathway: A crucial hinge relates Ca2+
signal with cardiomyocyte hypertrophy. Zhonghua Nei Ke Za Zhi.
43:19–21. 2004.(In Chinese). PubMed/NCBI
|
|
44
|
Wilkins BJ, Dai YS, Bueno OF, Parsons SA,
Xu J, Plank DM, Jones F, Kimball TR and Molkentin JD:
Calcineurin/NFAT coupling participates in pathological, but not
physiological, cardiac hypertrophy. Circ Res. 94:110–118. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Molkentin JD, Lu JR, Antos CL, Markham B,
Richardson J, Robbins J, Grant SR and Olson EN: A
calcineurin-dependent transcriptional pathway for cardiac
hypertrophy. Cell. 93:215–228. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Daskoulidou N, Zeng B, Berglund LM, Jiang
H, Chen GL, Kotova O, Bhandari S, Ayoola J, Griffin S, Atkin SL, et
al: High glucose enhances store-operated calcium entry by
upregulating ORAI/STIM via calcineurin-NFAT signalling. J Mol Med
(Berl). 93:511–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Somvanshi RK, Zou S, Qiu X and Kumar U:
Somatostatin receptor-2 negatively regulates β-adrenergic receptor
mediated Ca(2+) dependent signaling pathways in H9c2
cells. Biochim Biophys Acta. 1843:735–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsu SC, Chang YT and Chen CC: Early growth
response 1 is an early signal inducing Cav3.2 T-type calcium
channels during cardiac hypertrophy. Cardiovasc Res. 100:222–230.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee SD, Kuo WW, Lin DY, Chen TH, Kuo WH,
Hsu HH, Chen JZ, Liu JY, Yeh YL and Huang CY: Role of calcineurin
in Porphyromonas gingivalis-induced myocardial cell hypertrophy and
apoptosis. J Biomed Sci. 13:251–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Strack S, Wadzinski BE and Ebner FF:
Localization of the calcium/calmodulin-dependent protein
phosphatase, calcineurin, in the hindbrain and spinal cord of the
rat. J Comp Neurol. 375:66–76. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Smedler E and Uhlén P: Frequency decoding
of calcium oscillations. Biochim Biophys Acta. 1840:964–969. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fric J, Zelante T, Wong AY, Mertes A, Yu
HB and Ricciardi-Castagnoli P: NFAT control of innate immunity.
Blood. 120:1380–1389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sommerer C, Meuer S, Zeier M and Giese T:
Calcineurin inhibitors and NFAT-regulated gene expression. Clin
Chim Acta. 413:1379–1386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Maguire O, Tornatore KM, O'loughlin KL,
Venuto RC and Minderman H: Nuclear translocation of nuclear factor
of activated T cells (NFAT) as a quantitative pharmacodynamic
parameter for tacrolimus. Cytometry A. 83:1096–1104. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hess P: Calcium channels in vertebrate
cells. Annu Rev Neurosci. 13:337–356. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rampe D and Triggle DJ: New synthetic
ligands for L-type voltage-gated calcium channels. Prog Drug Res.
40:191–238. 1993.PubMed/NCBI
|
|
57
|
Katz AM: Calcium channel diversity in the
cardiovascular system. J Am Coll Cardiol. 28:522–529. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Triggle DJ: Calcium-channel antagonists:
Mechanisms of action, vascular selectivities, and clinical
relevance. Cleve Clin J Med. 59:617–627. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wild AR, Sinnen BL, Dittmer PJ, Kennedy
MJ, Sather WA and Dell'Acqua ML: Synapse-to-nucleus communication
through NFAT is mediated by L-type Ca2+ channel
Ca2+ spike propagation to the Soma. Cell Rep.
26:3537–3550.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cohn JN, Ferrari R and Sharpe N: Cardiac
remodeling-concepts and clinical implications: A consensus paper
from an international forum on cardiac remodeling. Behalf of an
international forum on cardiac remodeling. J Am Coll Cardiol.
35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yamazaki T, Komuro I, Zou Y, Kudoh S,
Shiojima I, Mizuno T, Hiroi Y, Nagai R and Yazaki Y: Efficient
inhibition of the development of cardiac remodeling by a
long-acting calcium antagonist amlodipine. Hypertension. 31:32–38.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sandmann S, Claas R, Cleutjens JP, Daemen
MJ and Unger T: Calcium channel blockade limits cardiac remodeling
and improves cardiac function in myocardial infarction-induced
heart failure in rats. J Cardiovasc Pharmacol. 37:64–77. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lu JC, Cui W, Zhang HL, Liu F, Han M, Liu
DM, Yin HN, Zhang K and Du J: Additive beneficial effects of
amlodipine and atorvastatin in reversing advanced cardiac
hypertrophy in elderly spontaneously hypertensive rats. Clin Exp
Pharmacol Physiol. 36:1110–1119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liao Y, Asakura M, Takashima S, Kato H,
Asano Y, Shintani Y, Minamino T, Tomoike H, Hori M and Kitakaze M:
Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR
phosphorylation. Biochem Biophys Res Commun. 327:1083–1087. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yu GL, Liang XQ and Zheng JQ: Contrast of
losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and
left ventricular remolding in hypertensive rats. Hunan Yi Ke Da Xue
Xue Bao. 26:405–408. 2001.(In Chinese). PubMed/NCBI
|
|
66
|
Meo M, Meste O, Signore S, Sorrentino A,
Cannata A, Zhou Y, Matsuda A, Luciani M, Kannappan R, Goichberg P,
et al: Reduction in Kv current enhances the temporal dispersion of
the action potential in diabetic myocytes: Insights from a novel
repolarization algorithm. J Am Heart Assoc. 5:e0030782016.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sung HH, Kam SC, Lee JH, Chae MR, Hong C,
Ko M, Han DH, So I and Lee SW: Molecular and functional
characterization of ORAI and STIM in human corporeal smooth muscle
cells and effects of the transfer of their dominant-negative mutant
genes into diabetic rats. J Urol. 187:1903–1910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu CZ, Tan JX, Wang Y, Huang YG and Huang
DL: L-type calcium channel blocker suppresses calcineurin signal
pathway and development of right ventricular hypertrophy. J Formos
Med Assoc. 104:798–803. 2005.PubMed/NCBI
|
|
69
|
Zou Y, Yamazaki T, Nakagawa K, Yamada H,
Iriguchi N, Toko H, Takano H, Akazawa H, Nagai R and Komuro I:
Continuous blockade of L-type Ca2+ channels suppresses
activation of calcineurin and development of cardiac hypertrophy in
spontaneously hypertensive rats. Hypertens Res. 25:117–124. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bugyei-Twum A, Advani A, Advani SL, Zhang
Y, Thai K, Kelly DJ and Connelly KA: High glucose induces Smad
activation via the transcriptional coregulator p300 and contributes
to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol.
13:892014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen Y, Yuan J, Jiang G, Zhu J, Zou Y and
Lv Q: Lercanidipine attenuates angiotensin II-induced cardiomyocyte
hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4
signaling. Mol Med Rep. 16:4545–4552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liu CJ, Cheng YC, Lee KW, Hsu HH, Chu CH,
Tsai FJ, Tsai CH, Chu CY, Liu JY, Kuo WW and Huang CY:
Lipopolysaccharide induces cellular hypertrophy through
calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol
Cell Biochem. 313:167–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
